PHOTO
Dubai: A more than 30-strong delegation of senior business leaders and investors have visited Dubai Science Park, a science and healthcare-focused business community, to discuss innovation, business opportunities and collaboration in the UAE’s world-class medical sector.
Under the glistening headquarters designed by architecture studio HDR and flanked by a world-class, environmentally-friendly laboratory complex, an elite group of international investors and corporate executives received an update on investment opportunities following years of strong healthcare spending in Dubai and the UAE.
Marwan Abdulaziz Janahi, Managing Director of Dubai Science Park, said: “These challenging months have refocused the greatest minds on the importance of scientific, medical and pharmaceutical innovation. It has catalysed a greater focus around collaboration, fostering an entrepreneurial spirit and providing a platform for talent to thrive. We were delighted to welcome such a distinguished delegation of high-ranking officials to our community, which is aligned with the UAE’s vision for a sustainable, knowledge-based economy, to explore investment opportunities.”
Healthcare expenditure in Dubai increased by 12% per annum between 2012 and 2017, according to public data from the Dubai Health Authority, and there remains plenty of opportunities for investment and growth in the sector moving forwards.
Key areas include centres of excellence in certain specialities such as the treatment of diabetes and cardiovascular diseases, home-based care and rehabilitation services. There are also opportunities to build sustainable public-private partnership models in Dubai, as well as areas of growth for digital healthcare companies as remote patient monitoring and care delivered through telehealth platforms becomes more common.
Among the senior figures in attendance were Dr Ibtesam Al Bastaki, Director of Investment and Public-Private Partnerships at Dubai Health Authority; Dr Ashraf Allam, Regional Vice President, Middle East, Africa & Turkey at Mundipharma; Majid Kaddoumi, President Central & Eastern Europe, Middle East & Africa of Medtronic; and Ashraf Radwan, CEO of the Healthcare Sector Yas Holding.
Established in 2005, Dubai Science Park is home to more than 350 companies, 3,600 professionals and organisations such as Pfizer, Thermo Fisher Scientific, Bio-Rad and Bayer. Designed with state-of-the-art infrastructure and services to improve ease of doing business, it has become a supportive and enabling ecosystem for entrepreneurs, startups and multinational corporations engaged in various scientific verticals.
-Ends-
About Dubai Science Park
Founded in 2005, Dubai Science Park (DSP) is a vibrant, holistic community dedicated to supporting entrepreneurs, SMEs and MNEs active in the sciences, energy and environmental sectors. With its ample office and laboratory space and robust infrastructure, DSP has created an enabling science-focused ecosystem that is home to more than 350 companies, employing over 3,700 professionals.
Through fostering growth, creativity, research and innovation in the areas of human science, plant science, material science, environmental science and energy science, DSP aims to play a significant role in facilitating a more sustainable and self-sufficient future that maximises the use of indigenous resources and talent.
For more information, please visit www.dsp.ae
For media enquiries, please contact:
Oscar Rousseau
APCO Worldwide
Email: orousseau@apcoworldwide.com
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
